Extended Data Fig. 6: Inhibition of PI3K/mTOR pathway signaling in KPC tumors and normal tissues in response to MTX-531.
a, Comparative cellular potency of MTX-531, erlotinib and alpelisib against EGFR and PI3K signaling in KPC cells. Cells were treated with the indicated drug for 2 hours across a broad dose range followed by immunoblot analysis. Densitometry was carried out to determine comparative EC50 values (right panel). Data are representative of two independent experiments. b, MTX-531 inhibits PI3K/mTOR signaling in KPC tumors. Pharmacodynamic modulation of PI3K/mTOR signaling in KPC tumors excised from mice (n = 3 tumors/group) treated with a single oral dose of MTX-531. Tumors were harvested at the indicated time point followed by immunoblot analysis. c, Evaluation of PI3K/mTOR pathway expression in liver and gastrocnemius (muscle) tissue excised from mice (n = 3 samples per tissue type) treated with a single oral dose of MTX-531 at 100 mg/kg. Tissues were harvested at two hours followed by immunoblot analysis. Representative data are shown from two independent experiments.
